Stockreport

Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex Therapeutics Ltd - American Depositary Shares  (ADXN) 
PDF Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase [Read more]